TheraRadar

Pharma Intelligence, Simplified

Landscape → Dermatology

Vitiligo

77 clinical trials

38 active
/
77 total (since 2015)
6
Phase 1 Active
9 total
19
Phase 2 Active
45 total
11
Phase 3 Active
19 total
5
Phase 4 Active
10 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Incyte Corporation 4 8 0
Pfizer 2 2 0
Jiangsu HengRui Medicine Co., Ltd. 2 0 0
AbbVie 1 1 0
Hudson Biotech 1 0 0
Novartis 1 0 0
Teva Branded Pharmaceutical Products R&D LLC 1 0 0
Takeda 1 0 0
CAGE Bio Inc. 1 0 0
Elixiron Immunotherapeutics (Hong Kong) Ltd. 1 0 0
Jiangsu vcare pharmaceutical technology co., LTD 1 0 0
Dren Bio 1 0 0
Forte Biosciences, Inc. 1 0 0
Minghui Pharmaceutical (Hangzhou) Ltd 1 0 0
Vyne Therapeutics Inc. 1 0 0
NCT06113445 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Incyte Corporation n=467
NCT06113471 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Incyte Corporation n=450
NCT06548360 RECRUITING
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation n=180
NCT06804811 RECRUITING
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Incyte Corporation n=250
NCT06118411 ACTIVE NOT RECRUITING
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie n=614
NCT06163326 RECRUITING
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Pfizer n=400
NCT06072183 ACTIVE NOT RECRUITING
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
Pfizer n=1,571
NCT07047612 RECRUITING
ICP-332 in Subjects With Non-segmental Vitiligo
Beijing InnoCare Pharma Tech Co., Ltd. n=603
NCT06109649 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Clinuvel, Inc. n=200
NCT06768840 RECRUITING
Vitiligo, New Treatment and Serum s100B
South Valley University n=50
NCT06719024 RECRUITING
Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Hospital Authority, Hong Kong n=20
NCT05583526 COMPLETED
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
Pfizer n=607
NCT04052425 COMPLETED
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Incyte Corporation n=330
NCT04057573 COMPLETED
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Incyte Corporation n=344
NCT04530344 COMPLETED
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Incyte Corporation n=458
NCT04942860 COMPLETED
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
Nicolaus Copernicus University n=25
NCT05513924 COMPLETED
Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.
South Valley University n=40
NCT04774809 TERMINATED
Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
Reistone Biopharma Company Limited n=75
NCT02466997 COMPLETED
Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC
University Hospital, Bordeaux n=42

Data: ClinicalTrials.gov